About: Innovative approach for improved rFVIII concentrate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Innovative approach for improved rFVIII concentrate Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Innovative approach for improved rFVIII concentrate
Creator	Morfini, Massimo Correspondence, Massimo Morfini,
Source	Medline; PMC
abstract	The development of a new recombinant factor VIII was designed and implemented to answer a number of unmet needs of patients affected by hemophilia A. Turoctocog alfa is bioengineered in a specific Chinese hamster ovary clone to present translational and posttranslational characteristics (sulphation, glycosylation) biosimilar to natural circulating forms of FVIII, with the aim to devoid any minimal change which may impact immunogenicity and antigenicity of recombinant protein. Both producer cell line and media are maintained free of any animal or human plasma derivative. Downstream processes of purification are performed by five steps (immunoaffinity chromatography, ion‐exchange chromatography, virus inactivation by means of solvent‐detergent treatment and nanofiltration, and to end with gel filtration), to provide the best possible margin of safety from known and unknown infectious agents. Large clinical trials seem to confirm the expectations placed in Turoctocog alfa in terms of high quality and safety of recombinant FVIII toward the goal of overcoming actual and future challenges of hemophilia therapy.
has issue date	2014-05-22(xsd:dateTime)
bibo:doi	10.1111/ejh.12359
bibo:pmid	24766411
has license	no-cc
sha1sum (hex)	ba8f0b70e20b481ecdd144d6af527611cdbf7804
schema:url	https://doi.org/10.1111/ejh.12359
resource representing a document's title	Innovative approach for improved rFVIII concentrate
has PubMed Central identifier	PMC7163506
has PubMed identifier	24766411
schema:publication	Eur J Haematol
resource representing a document's body	covid:ba8f0b70e20b481ecdd144d6af527611cdbf7804#body_text
is schema:about of	named entity 'circulating' named entity 'immunogenicity' named entity 'posttranslational' named entity 'specific' named entity 'natural' named entity 'ANTIGENICITY' named entity 'PERFORMED BY' named entity 'PLACED' named entity 'MEANS' named entity 'GLYCOSYLATION' named entity 'CHANGE' named entity 'POSTTRANSLATIONAL' named entity 'DETERGENT' named entity 'ANIMAL' named entity 'BIOENGINEERED' named entity 'GEL FILTRATION' named entity 'CHALLENGES' named entity 'TO PROVIDE' named entity 'SPECIFIC' named entity 'hemophilia A' named entity 'recombinant protein' named entity 'plasma' named entity 'antigenicity' named entity 'factor VIII' named entity 'biosimilar' named entity 'therapy' named entity 'margin' named entity 'ion-exchange chromatography' named entity 'solvent' named entity 'posttranslational' named entity 'infectious agents' named entity 'biosimilar' named entity 'Chinese hamster ovary' named entity 'human plasma' named entity 'antigenicity' named entity 'nanofiltration' named entity 'solvent' named entity 'antibody' named entity 'antibody' named entity 'culture media' named entity 'Turoctocog alfa' named entity 'detergent' named entity 'protein' named entity 'resin' named entity 'nanofiltration' named entity 'plasma half-life' named entity 'HBV' named entity 'antibodies' named entity 'prion' named entity 'enveloped viruses' named entity 'parvoviruses' named entity 'adverse events' named entity 'solvent' named entity '95%' named entity 'mAb' named entity 'Turoctocog alfa' named entity 'native structure' named entity 'hemophiliacs' named entity 'bioengineering' named entity 'host cells' named entity 'albumin' named entity 'glycosylation' named entity 'cross-species transmission' named entity 'electrical charges' named entity 'hemophilia' named entity 'Turoctocog alfa' named entity 'chromatographic' named entity 'pathogen' named entity 'Factor VIII' named entity 'insomnia' named entity 'Turoctocog alfa' named entity 'CHO' named entity 'circoviruses' named entity 'prion protein' named entity 'mammalian cell' named entity 'EMA' named entity 'cell line' named entity 'Turoctocog alfa' named entity 'subclinical'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software